COHERUS BIOSCIENCES INC. - COMMON STOCK

Coherus to Acquire Surface Oncology

16 6 2023 06:01:00 提供 Nasdaq GlobeNewswire

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma

05 6 2023 16:30:00 提供 Nasdaq GlobeNewswire

Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients

01 6 2023 07:33:07 提供 Nasdaq GlobeNewswire

Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023

01 6 2023 07:30:00 提供 Nasdaq GlobeNewswire

Coherus Announces U.S. Launch of UDENYCA® Autoinjector

22 5 2023 07:30:00 提供 Nasdaq GlobeNewswire

Coherus Prices Public Offering of Common Stock

16 5 2023 05:50:00 提供 Nasdaq GlobeNewswire

Coherus Announces Proposed Public Offering of Common Stock

15 5 2023 15:01:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

08 5 2023 15:05:02 提供 Nasdaq GlobeNewswire

Coherus BioSciences to Present at Upcoming Investor Conferences in May

04 5 2023 15:30:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023

01 5 2023 15:07:00 提供 Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

27 4 2023 07:05:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results

06 3 2023 15:01:00 提供 Nasdaq GlobeNewswire

FDA Approves UDENYCA® Autoinjector

06 3 2023 07:00:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences to Present at Upcoming Investor Conferences in March

01 3 2023 07:25:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

28 2 2023 07:25:00 提供 Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

15 2 2023 07:25:00 提供 Nasdaq GlobeNewswire

Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services

13 2 2023 07:25:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

03 2 2023 16:30:09 提供 Nasdaq GlobeNewswire

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

09 1 2023 07:20:00 提供 Nasdaq GlobeNewswire

Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 1 2023 06:01:00 提供 Nasdaq GlobeNewswire